ERYTHROPOIETIC PROTOPORPHYRIA (EPP)
Clinical trials for ERYTHROPOIETIC PROTOPORPHYRIA (EPP) explained in plain language.
Never miss a new study
Get alerted when new ERYTHROPOIETIC PROTOPORPHYRIA (EPP) trials appear
Sign up with your email to follow new studies for ERYTHROPOIETIC PROTOPORPHYRIA (EPP), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug could let people with rare sun allergy enjoy the outdoors longer
Disease control OngoingThis study tests whether the drug bitopertin can help people with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP) spend more time in sunlight without pain. About 183 participants aged 12 and older will receive either bitopertin or a placebo for 6 months. Rese…
Matched conditions: ERYTHROPOIETIC PROTOPORPHYRIA (EPP)
Phase: PHASE3 • Sponsor: Disc Medicine, Inc • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New pill could let sunlight-sensitive patients enjoy the sun longer without burning pain
Symptom relief OngoingThis study tests an experimental drug called MT-7117 in 165 people aged 12 to 75 who have erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP), conditions that cause severe pain from sunlight exposure. Participants are randomly assigned to receive either the drug …
Matched conditions: ERYTHROPOIETIC PROTOPORPHYRIA (EPP)
Phase: PHASE3 • Sponsor: Tanabe Pharma America, Inc. • Aim: Symptom relief
Last updated May 01, 2026 15:59 UTC